Edition:
United States

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

77.92EUR
11:36am EDT
Change (% chg)

€0.24 (+0.31%)
Prev Close
€77.68
Open
€77.68
Day's High
€77.92
Day's Low
€77.22
Volume
318,800
Avg. Vol
337,253
52-wk High
€78.30
52-wk Low
€56.55

Chart for

About

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.86
Market Cap(Mil.): €15,101.42
Shares Outstanding(Mil.): 194.51
Dividend: 1.18
Yield (%): 1.06

Financials

  UCB.BR Industry Sector
P/E (TTM): 16.77 28.11 30.17
EPS (TTM): 4.63 -- --
ROI: 11.13 12.95 12.67
ROE: 15.02 14.96 14.86

CORRECTED-BRIEF-UCB's Midazolam Nasal Spray Granted Orphan Drug Designation

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) TO REVIEW MIDAZOLAM NASAL SPRAY

Aug 13 2018

BRIEF-Cimzia Is The First Therapy To Demonstrate Positive Results In A 52-Week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

* CIMZIA® (CERTOLIZUMAB PEGOL) IS THE FIRST THERAPY TO DEMONSTRATE POSITIVE RESULTS IN A 52-WEEK, PLACEBO CONTROLLED NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STUDY

May 16 2018

BRIEF-UCB Announces Positive CHMP Opinion For Cimzia®

* UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

Apr 27 2018

BRIEF-UCB Q1 Revenue Down At 1.07 Billion Euros

* FINANCIAL OUTLOOK 2018 CONFIRMED: REVENUE EXPECTED TO REACH € 4.5 - 4.6 BILLION

Apr 25 2018

BRIEF-UCB Acquires Midazolam Nasal Spray From Proximagen

* UCB TO EXPAND EPILEPSY PORTFOLIO WITH STRATEGIC ACQUISITION OF MIDAZOLAM NASAL SPRAY FROM PROXIMAGEN

Apr 20 2018

BRIEF-UCB Acquires Element Genomics

* UCB STRENGTHENS RESEARCH CAPABILITIES WITH ACQUISITION OF ELEMENT GENOMICS, A DUKE UNIVERSITY BIOTECH SPIN-OFF

Apr 05 2018

BRIEF-UCB: Publication On Cimzia® Shows Psoriatic Arthritis Patients Achieved Treatment Targets

* PUBLICATION ON CIMZIA® SHOWS PSORIATIC ARTHRITIS PATIENTS ACHIEVED TREATMENT TARGETS

Apr 03 2018

BRIEF-UCB Files For Acceptance With China Food And Drug Administration For Cimzia

* UCB ANNOUNCES FILING ACCEPTANCE WITH CHINA FOOD AND DRUG ADMINISTRATION FOR CIMZIA FOR TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

Mar 30 2018

BRIEF-UCB SA U.S. Food And Drug Administration (FDA) Approves Label Change For UCB’S Cimzia®

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES LABEL CHANGE FOR UCB’S CIMZIA®

Mar 22 2018

BRIEF-UCB FY Net Sales Up At ‍​4.18 Billion Euros

* FY: REVENUE EUR 4.53‍​ BILLION VERSUS EUR 4.43 BILLION IN REUTERS POLL, NET SALES EUR ‍​4.18 BILLION VERSUS EUR 3.83 BILLION YEAR AGO

Feb 22 2018

Earnings vs. Estimates